Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Peregrine Pharmaceuticals Appoints New CEO | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Peregrine Pharmaceuticals Appoints New CEO

Roger Lias currently sits on the company's board of directors

By: Betsy Louda

, Contract Pharma

Peregrine Pharmaceuticals announced the appointment of Roger J. Lias, Ph.D., as the company’s new president and chief executive officer.  

 

Dr. Lias, who has more than 20 years of contract development and manufacturing organization (CDMO) management experience, currently sits on the Peregrine board of directors and serves as president of Avid Bioservices, Peregrine’s wholly-owned CDMO subsidiary.   As part of this transformation, Peregrine is actively implementing a multi-pronged strategic plan designed to diversify and broaden its customer base and project mix, expand and strengthen its CDMO service offerings, and drive increased growth and profitability.  Additionally, Peregrine is in the process of officially changing the company’s name to Avid Bioservices and adopting a new NASDAQ ticker symbol.  The company expects this process to be completed in early 2018.

 

“We believe that Roger is best equipped to lead Peregrine, including the completion of the company’s transition to a pure play CDMO operating under the Avid Bioservices name.  With the demand for biologics manufacturing exceeding the industry’s current capacity and expected to continue to grow in coming years, Roger and his team have worked aggressively to establish a strategic plan that we anticipate will allow the company to take advantage of this significant market opportunity.  The team has already made important progress implementing this plan and we look forward to their continued execution of the strategy to best position our CDMO business for success,” said Joseph Carleone, Ph.D., chairman of Peregrine. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters